Matching articles for "Issue 1311"
Fenofibric Acid (Trilipix)
The FDA has approved the marketing of fenofibric acid ( Trilipix - Abbott) to reduce triglycerides and increase HDL-C in patients with mixed dyslipidemia on optimal doses of a HMG-CoA reductase inhibitor…
Med Lett Drugs Ther. 2009 May 4; 51(1311):33-4
The FDA has approved the marketing of fenofibric acid ( Trilipix - Abbott) to reduce triglycerides and increase HDL-C in patients with mixed dyslipidemia on optimal doses of a HMG-CoA reductase inhibitor (statin) who have, or have risk factors for, coronary heart disease. It is the first fibrate approved by the FDA specifically for combined use with a statin. Trilipix is also approved as monotherapy for hypertriglyceridemia, hypercholesterolemia and low HDL-C. The patent for Tricor, Abbott's older formulation of fenofibrate, will expire in 2011.
Fesoterodine (Toviaz) for Overactive Bladder
The FDA has approved the marketing of fesoterodine ( Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this indication.
Med Lett Drugs Ther. 2009 May 4; 51(1311):34-5
The FDA has approved the marketing of fesoterodine ( Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this indication.
Drugs for MRSA with Reduced Susceptibility to Vancomycin
The recent Medical Letter article on vancomycin dosing and monitoring briefly mentioned use of an alternative antibiotic for treatment of methicillin-resistant Staphylococcus aureus (MRSA) with reduced…
Med Lett Drugs Ther. 2009 May 4; 51(1311):36
The recent Medical Letter article on vancomycin dosing and monitoring briefly mentioned use of an alternative antibiotic for treatment of methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Some readers have asked for more information on this subject. Click here to view the free full article.
